
© 2024 Der Aktionär
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mo | Bristol-Myers Squibb Aktie: Auf's Glatteis geführt? | Trotz FDA-Aktualisierung für Camzyos verliert Bristol-Myers Squibb weiter an Wert. Analysten bleiben skeptisch nach Kurszielsenkungen. Die Aktie von Bristol-Myers Squibb zeigt sich am heutigen Handelstag... ► Artikel lesen | |
Mo | Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach | ||
Mo | Goldman Sachs holds neutral on Bristol-Myers with $55 target | ||
Do | Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings? | ||
Mi | Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
01.04. | Cantor Fitzgerald maintains overweight on Immatics stock | ||
27.03. | Immatics GAAP EPS of €0.14 beats, revenue of $161.9M | ||
27.03. | Immatics N.V. - 6-K, Report of foreign issuer | ||
27.03. | Immatics Announces Full Year 2024 Financial Results and Business Update | Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203... ► Artikel lesen | |
27.03. | Immatics N.V. - 20-F, Annual and transition report of foreign private issuers |
Unternehmen / Aktien | Kurs | % |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | 42,995 | -0,67 % |
IMMATICS NV | 3,696 | -1,23 % |